Antiviral activity of FNC, 2′-deoxy-2′-β-fluoro-4′- azidocytidine, against human and duck HBV replication

Antiviral Therapy

Volumn 17, Issue 4, 2012, Pages 679-687

  Zheng, Liyun ^a   Wang, Qiang ^a   Yang, Xiaorui ^a   Guo, Xiaohe ^b   Chen, Lu ^c   Tao, Le ^b   Dong, Lihong ^b   Li, Yujiang ^b   An, Haoyun ^b   Yu, Xuejun ^b   Wang, Qingduan ^a   Chang, Junbiao ^a  

^a ZHENGZHOU UNIVERSITY   (China)

^b Henan Key Laboratory of Fine Chemicals   (China)

^c HENAN AGRICULTURAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2' DEOXY 2' BETA FLUORO 4' AZIDOCYTIDINE; CYTIDINE DERIVATIVE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; UNCLASSIFIED DRUG; VIRUS DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CELL STRAIN HEPG2; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DUCK; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER HISTOLOGY; MALE; NONHUMAN; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; AZIDES; CELL LINE, TUMOR; DEOXYCYTIDINE; DUCKS; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATOCYTES; HUMANS; LAMIVUDINE; LIVER; VIRUS REPLICATION;

EID: 84861674959     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP2094     Document Type: Article

References (31)

1. Srivastav NC, Shakya N, Mak M, Agrawal B, Tyrrell DL, Kumar R. Antiviral activity of various 1-(2′-deoxy-beta-D-lyxofuranosyl), 1-(2′-fluoro-beta-D-xylofuranosyl), 1-(3′-fluoro-beta-D- arabinofuranosyl), and 2′-fluoro-2′,3′-didehydro-2′, 3′-dideoxyribose pyrimidine nucleoside analogues against duck hepatitis B virus (DHBV) and human hepatitis B virus (HBV) replication. J Med Chem 2010; 53:7156-7166.
2. Fan JM, Zhang Q, Xu J, et al. Inhibition on hepatitis B virus in vitro of recombinant MAP30 from bitter melon. Mol Biol Rep 2009; 36:381-388.
3. Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis 2002; 2:479-486. (Pubitemid 34826853)
4. Wu JM, Lin JS, Xie N, Liang KH. Inhibition of hepatitis B virus by a novel l-nucleoside, beta-L-D4A and related analogues. World J Gastroenterol 2003; 9:1840-1843. (Pubitemid 37038144)
5. Delaney WE, Miller TG, Isom HC. Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (-)-beta-2′,3′- dideoxy-3′-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA. Antimicrob Agents Chemother 1999; 43:2017-2026. (Pubitemid 29395202)
6. Guo Q, Zhao L, You Q, et al. Anti-hepatitis B virus activity of wogonin in vitro and in vivo. Antiviral Res 2007; 74:16-24. (Pubitemid 46366014)
7. Wang Q, Liu X, Zhang Y, et al. FNC, a novel nucleoside analogue inhibits cell proliferation and tumor growth in a variety of human cancer cells. Biochem Pharmacol 2011; 81:848-855.
8. Ohrui H, Kohgo S, Hayakawa H, et al. 2′-Deoxy-4′-C-ethynyl-2- fluoroadenosine: a nucleoside reverse transcriptase inhibitor with highly potent activity against all HIV-1 strains, favourable toxic profiles and stability in plasma. Nucleic Acids Symp Ser (Oxf) 2006; 50:1-2.
9. Klumpp K, Kalayanov G, Ma H, et al. 2′-Deoxy-4′-azido nucleoside analogs are highly potent inhibitors of hepatitis C virus replication despite the lack of 2′-alpha-hydroxyl groups. J Biol Chem 2008; 283:2167-2175.
10. Gao LL, Wang XY, Lin JS, Zhang YH, Li Y. Efficacies of beta-l-D4A against hepatitis B virus in 2.2.15 cells. World J Gastroenterol 2008; 14:1263-1267. (Pubitemid 351356337)
11. Jahn B, Martin E, Stueben A, Bhakdi S. Susceptibility testing of Candida albicans and Aspergillus species by a simple microtiter menadione-augmented 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay. J Clin Microbiol 1995; 33:661-667.
12. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65:55-63. (Pubitemid 14203433)
13. Ferrari M, Fornasiero MC, Isetta AM. MTT colorimetric assay for testing macrophage cytotoxic activity in vitro. J Immunol Methods 1990; 131:165-172. (Pubitemid 20241516)
14. Pang R, Tao J, Zhang S, et al. In vitro anti-hepatitis B virus effect of Hypericum perforatum L. J Huazhong Univ Sci Technolog Med Sci 2010; 30:98-102.
15. Liu Y-K, Zheng L, Chang J-B, et al. Development and application of real-time PCR assay for detection of duck hepatitis B virus. Journal of Yangzhou University (Agricultural and Life Science Edition) 2010; 31:7-12.
16. Li J, Huang H, Feng M, Zhou W, Shi X, Zhou P. In vitro and in vivo anti-hepatitis B virus activities of a plant extract from Geranium carolinianum L. Antiviral Res 2008; 79:114-120.
17. Günther S, Li BC, Miska S, Krüger DH, Meisel H, Will H. A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immonusuppressed patients. J Virol 1995; 69:5437-5444.
18. Marion PL, Salazar FH, Winters MA, Colonno RJ. Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication. Antimicrob Agents Chemother 2002; 46:82-88. (Pubitemid 34031606)
19. Xie HY, Xia WL, Zhang CC, et al. Evaluation of hepatitis B virus replication and proteomic analysis of HepG2.2.15 cell line after cyclosporine A treatment. Acta Pharmacol Sin 2007; 28:975-984.
20. Liu T, Zhao J, Li H, Ma L. Evaluation on anti-hepatitis viral activity of Vitis vinifer L. Molecules 2010; 15:7415-7422.
21. Lai CL, Yuen MF. Profound suppression of hepatitis B virus replication with lamivudine. J Med Virol 2000; 61:367-373. (Pubitemid 30368540)
22. He YW, Guo CX, Pan YF, Peng C, Weng ZH. Inhibition of hepatitis B virus replication by pokeweed antiviral protein in vitro. World J Gastroenterol 2008; 14:1592-1597. (Pubitemid 351460178)
23. Levine S, Hernandez D, Yamanaka G, et al. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother 2002; 46:2525-2532. (Pubitemid 34793459)
24. Lin M, Yang LY, Li WY, Peng YP, Zheng JK. Inhibition of the replication of hepatitis B virus in vitro by oxymatrine. J Int Med Res 2009; 37:1411-1419.
25. Han YQ, Huang ZM, Yang XB, Liu HZ, Wu GX. In vivo and in vitro anti-hepatitis B virus activity of total phenolics from Oenanthe javanica. J Ethnopharmacol 2008; 118:148-153.
26. Zoulim F. Therapy of chronic hepatitis B virus infection: inhibition of the viral polymerase and other antiviral strategies. Antiviral Res 1999; 44:1-30. (Pubitemid 29505328)
27. Schiller JT, Lowy DR. Vaccines to prevent infections by oncoviruses. Annu Rev Microbiol 2010; 64:23-41.
28. Li CQ, Zhu YT, Zhang FX, et al. Anti-HBV effect of liposome-encapsulated matrine in vitro and in vivo. World J Gastroenterol 2005; 11:426-428.
29. Chu CK, Boudinot FD, Peek SF, et al. Preclinical investigation of l-FMAU as an anti-hepatitis B virus agent. Antivir Ther 1998; 3:113-121. (Pubitemid 28528327)
30. Chen YX, Huang AL, Qi ZY, Shan YL, Sun H. Assessment of a method for detecting serum HBV DNA with HBV DNA probe labelled directly by alkaline phosphatise. Hepatobiliary Pancreat Dis Int 2003; 2:553-556. (Pubitemid 37441674)
31. Dong B, Shao XW, Tao PZ. Inhibition of duck hepatitis B virus DNA replication by antisense phosphorothioate oligodeoxynucleotides in vitro and in vivo. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2003; 17:25-27.